Conclusions: The presence of false lumen thrombus is associated with an increase in long-term aorta related morbidity and mortality. These findings may have implications on risk stratification, frequency of surveillance imaging, and future treatments.

**TCT-543**

Covered Endovascular Reconstruction of Aortic Bifurcation or CERAB-technique for treating extensive aortoiliac occlusive disease.

Peter Goverde,1 Michel Reijnen2
1ZNA Stuivenberg Hospital, Antwerp, Belgium, 2Kokura Memorial Hospital, Kitakyushu, Japan

Background: We developed the Covered Endovascular Reconstruction of Aortic Bifurcation or CERAB-technique for extensive and/or recurrent aortoiliac occlusive disease using V12 covered balloon expandable stents (Atrium Maquet Getinge Europe BV) to rebuild the aortic bifurcation.

Methods: Endovascular bifemoral recanalisation of the aortoiliac axes; placement and expansion of a 12 mm V12 Large Diameter in the distal aorta (9 Fr). Pick up of the already expanded V12 stent with an large balloon (adapted to the aortic diameter). The balloon is so positioned that the distal marker is about 15 mm proximal to the distal stent margin. After positioning and expansion, the distal stent part becomes funnel-shaped. Two iliac covered stent-grafts are then placed in this segment, in a ‘kissing-stent’ configuration and inflated. Both stents are now making a very tight combination with the aortic stent, as were they moulded together, simulating a new bifurcation.

Results: Two-centre prospective, non-randomised, follow-up study. We treated now 70 patients with acute, chronic or recurrent aortoiliac occlusive disease. Technical success rate up till now was almost 95%. Follow-up 52 – 1 months. 5 patients died of non-interventional causes. Five patients re-occuled, mainly due to progressive distal peripheral disease. They received successfully thrombolysis and treatment of the outflow problems. The other patients showed no complications.

Conclusions: Covered Endovascular Reconstruction of Aortic Bifurcation or CERAB is safe and feasible and can be performed completely percutaneous. A larger population, longer follow-up, further haemodynamic investigation is needed.

TCT-544

The Potential Role of Statin in Patients with Critical Limb Ischemia.

Atsushi Tosa1, Yoshimitsu Soga1, Osamu Iida1, Masato Nakamura1
1Kawakita General Hospital, Tokyo, Japan

Background: Revascularization is the optimal treatment to avoid major amputation for critical limb ischemia (CLI) patients. Although previous studies report that statin administration is associated with a reduced risk for cardiovascular events, the efficacy for CLI patients is unclear. In this study, we aimed to compare the outcomes in CLI patients with statin administration and without statin administration after endovascular therapy (EVT).

Methods: This study is a subanalysis from Endovascular Treatment for Infra-inguinal Revascularization (ER) mainly due to a higher ratio in hemorrhage complications. We have treated more than 100 patients with extensive distal femoropopliteal disease (TASC II C & D) with heavy calcifications, occlusions, recurrent disease, stent fractures etc. These lesions, that not responded to balloon angioplasty and that needed stent placement, were all treated with placement of Supera stents.

Results: Results of the single centre prospective AURORAA registry: Follow up done by ultrasound. Five patients died of non-interventional causes. Six months primary patency was more then 90%. Twelve months primary patency was around 81%. We observed further more no stent fractures or flow limiting kinking in this very difficult “to stent” area (distal superficial femoral artery & popliteal artery). Average lesion length: 14 cm; average stent length: 18 cm. Technical success rate 96%

Conclusions: The Supera stent can be a solution when the use of a “classic” nitinol stent is not indicated or favourable, especially in the femoropopliteal area. It has very good patency rates, despite the very difficult region to treat. This self expandable stent system can be a necessary complement in your tool box due to its special characteristics.

**TCT-545**

The AURORAA registry : 1 year results using interwoven nitinol stents for extensive distal femoropopliteal occlusive disease.

Peter Goverde,1 Katrien Lauwers2, Sven Vercauteren2
1ZNA Stuivenberg Hospital, Antwerp, Belgium, 2Vascular Clinic ZNA, Antwerp, Belgium

Background: In the endovascular treatment of extensive disease in the distal superficial femoral and popliteal level, you can encounter flow limiting problems, where stent placement is needed after balloon angioplasty. At the moment most of the standard bare nitinol stents will have difficulties in these areas. With the introduction of the Supera stent (IDEV Technologies, Inc., Texas, US) we may have an answer in treating those problematic lesions.

Methods: Because of the Supera stent new design; with 6 interwoven nitinol wires, it has extraordinary characteristics: very flexible, kink, fracture and crush resistant together with great radial force. We have treated more than 100 patients with extensive distal femoropopliteal disease (TASC II C & D) with heavy calcifications, occlusions, recurrent disease, stent fractures etc. These lesions, that not responded to balloon angioplasty and that needed stent placement, were all treated with placement of Supera stents.

Results: Results of the single centre prospective AURORAA registry: Follow up done by ultrasound. Five patients died of non-interventional causes. Six months primary patency was more then 90%. Twelve months primary patency was around 81%. We observed further more no stent fractures or flow limiting kinking in this very difficult “to stent” area (distal superficial femoral artery & popliteal artery). Average lesion length: 14 cm; average stent length: 18 cm. Technical success rate 96%

Conclusions: The Supera stent can be a solution when the use of a “classic” nitinol stent is not indicated or favourable, especially in the femoropopliteal area. It has very good patency rates, despite the very difficult region to treat. This self expandable stent system can be a necessary complement in your tool box due to its special characteristics.
discharge. Retroperitoneal bleeding, pseudoneuroma, arteriovenous fistula and hospitalization results from SFA stenting trials. Six different approaches of major vascular complications (MVC). Secondary endpoints were: death, stroke, myocardial infarction, amputation and target lesion revascularization (TLR).

Results: The study cohort had average age of 79 (range 70–95) years compared to 60.9 in the control group (range 38–69). Study group were more likely to be female, but less likely to be active smokers, diabetics or dialysis reliant (p < 0.001). There were no differences between groups in VCD deployment and clinical limb ischemia. The mean time to ambulation in the elderly and control group were 3.6 hours (±1.2) and 3.4 hours (±1.3) respectively (p = 0.8). In 24 hours as well as in 30 days follow up there were no significant differences in the primary and secondary endpoints between groups. Current smoking status (OR=2.35, 95% CI: 0.485- 11.6) in the octogenarians, whereas female sex (OR= 1.75, 95% CI: 0.389- 7.86) and hypercholesterolemia (OR= 0.739, 95% CI: 0.294- 154.4) in controls were found to be independent predictors of MVC at 30 days.

Conclusions: The same day discharge after ER on lower extremities is safe and feasible in the elderly.

TCT-547
Long term outcomes of percutaneous lower extremity arterial interventions with balloon angioplasty versus atherectomy- propensity score matched registry, Adam Janus1, Krzysztof P. Mielikowski1, Piotr P. Baszma1, Ksenia Kosteczko1, Magda Konkolewska1, Radoslaw Szymanski1, Buszman E. Pavel1, R. Stefan Kiec2
1Center of Cardiovascular Research and Development American Heart Of Poland, Katowice, Silesia, 2American Heart of Poland, Katowice, Silesia, 3American Heart of Poland, Katowice, Poland, 4Endovascular & Heart Institute, San Antonio, TX, 5Malopolskie Heart and Vessels Center in Chorzow, American Heart of Poland S.A., Katowice, Poland, 6American Heart of Poland, Ustron, Poland, 7Clinical Associate Professor of Medicine at UTHSCI in San Antonio, San Antonio, TX

Background: The atherosclerosis plaques have different morphology from soft neointimal plaques to hard calcified lesions. Therefore, we sought to evaluate the efficacy of percutaneous balloon angioplasty (PTA) versus atherectomy (AT) endovascular revascularization which type was attuned by operator. Methods: Between 2008 and 2013 a total of 419 endovascular revascularizations were performed on arteries of lower extremities. In this registry we include patients with claudication as well as with critical limb ischemia (CLI). The endpoints were considered as target lesion revascularization (TLR), amputation, major adverse cardiovascular event (MACE) and bailout stenting (BS). MACE was defined as death, myocardial infarction and stroke. The type of atherectomy (excisional- soft plaque, orbital- calcified plaque, with active aspiration- with a thrombus) was left to the operator’s discretion.

Results: The PTA was performed on 215 patients, whereas AT was used in 204 cases (Silver Hawk TM, EV3- MN, USA -125; CSI600M, MN- USA- 66 Pathway Medical Technologies- 13). The mean follow up time was 500 (±454) days. There were no significant differences in baseline characteristics between groups with the exception of increased coronary artery disease, dialysis and CLI for PTA group. There were significant differences in TVR (PTA: 32% vs. AT: 21%; p=0.01), death (PTA8% vs. AT: 2%; p=0.009) and BS (PTA9% vs. AT:1%;p=0.001). Kaplan- Mayer analysis showed no significant differences between groups in time to TLR, amputation, death. After adjustment this was sustained.

Conclusions: In this observational analysis, atherectomy endovascular revascularization offered better long term outcomes than balloon angioplasty.

TCT-548
Variability in Analysis of Freedom from Primary Patency from Trials Assessing Stent Implantation in the Superficial Femoral Artery, Moshe Vardi1, Lanvy Le1, Gheorghe Doros2
1Harvard Clinical Research Institute, Boston, MA, 2Boston University, Boston, MA

Background: Primary Patency (PP) in trials assessing Superficial Femoral Artery (SFA) stenting is defined as a combination of vessel patency assessed by duplex ultrasound (DUS) at 12 month visit and freedom from revascularization of the index vessel through 12 month follow-up. Patients are thus more likely to lose PP during the mandated DUS assessment. Moreover, DUS is performed within a pre-specified window which exceeds 12 months, thus the time frame for analyzing patency via DUS exceeds the time frame by which revascularization is captured. There are no guidelines as to the correct method for presenting these analysis in reports from clinical trials. We aimed to analyze the implications of applying different methods in assessing freedom from loss of PP in studies assessing stenting for SFA disease.

Methods: We simulated a dataset of patients and outcomes based on existing atherectomy results from SFA stenting trials. Six different approaches to Kaplan Meier (KM) analyses were applied based on entry criteria into and time frame of the KM model.

Results: Six KM estimates of freedom from loss of PP were generated for each of the 10,000 simulation sets. The six different methods averaged from 67.9% to 81.8%.

Conclusions: Survival analyses of freedom from loss of PP vary substantially according to the methods employed. This may lead to misrepresentation of results from clinical trials. The development of a unified approach is advocated.

TCT-549
Sub-analysis of the CONFIRM Registries: Outcomes in Claudicant Patients Treated for Peripheral Arterial Disease with Orbital Atherectomy, George Adams1, Jeffrey Innes1, Jihad A. Mustapha1, Robert W. Vorhies1
1Rex Healthcare, University of North Carolina, Raleigh, NC, 2Yale University School of Medicine, New Haven, CT, 3Metro Health Hospital, Grand Rapids, MI, 4Cox Health, Springfield, MO

Background: Intermittent claudication affects 2.5% of women and 5% of men over the age of 60. Advanced age, diabetes, and renal insufficiency predispose patients to intra-arterial calcium which is a predictor of poor endovascular treatment success. Methods of treating peripheral arterial disease (PAD) have evolved and now include minimally-invasive endovascular procedures, utilizing orbital atherectomy (OA) which can modify calcific plaque both above and below-the-knee. Methods: Three consecutive CONFIRM patient registries were conducted prospectively and enrolled patients on an “all-comers” basis to evaluate the use of atherectomy for peripheral artery obstructions. The primary endpoints included 90-day Major Adverse Events (MACE) and bailout stenting. Results of 315 patients enrolled in the CONFIRM I-III registries revealed 1698 patients with claudication (Rutherford Class I-3) and documented lesion morphology. We analyzed the CONFIRM series to compare procedural complications after OA treatment of lesions with moderate/severe calcium versus lesions without moderate/severe calcium in claudicant patients.

Results: Eighty-two percent of claudicants treated with OA had moderate/severely calcified lesions. There was no significant difference in the percentage of perforations (0.6% vs 0.0%), slow flow (2.9% vs 2.0%), closure (1.4% vs 2.3%), spasm (3.8% vs 6.3%), embolism (1.7% vs 2.6%), or thrombus (1.1% vs 1.3%), in claudicants with moderate/severely calcified lesions vs without moderate/severely calcified lesions, respectively. Claudicants with moderate/severe calcium had fewer dissections than those without moderate/severely calcified lesions (10.9% vs 16.2%, p=0.004).

Conclusions: The majority of the claudicant patients in this study had lesions with moderate to severe calcification, yet the occurrence of adverse events was low after treatment with orbital atherectomy. Orbital atherectomy is a safe tool for restoring blood flow in the lower extremities of claudicant patients regardless of arterial calcium burden.

TCT-550
Assessment of Stability and Bactericidal Activity of a Novel Triple Antimicrobial-Bonded Graft for Preventing Perioperative Aortic Infection, Ibrahim Aboshady1, Issam Raad2, Kamal G. Khalil3, L. Maximilian Buja1
1Texas Heart Institute, Houston, TX, 2MD Anderson Cancer Center, Houston, TX, 3The University of Texas HSC, Houston, TX

Background: Prosthetic aortic grafts remain problematic despite enhancements in biomaterials and production prosthetics, improved surgical techniques, and a better understanding of the pathogenesis of graft infections. Previously, we investigated the use of orbital atherectomy in peripheral lesions of the lower extremities. Analysis of 1045 patients enrolled in the CONFIRM I-III registries revealed 1698 patients with claudication (Rutherford Class I-3) and documented lesion morphology. We analyzed the CONFIRM series to compare procedural complications after OA treatment of lesions with moderate/severe calcium versus lesions without moderate/severe calcium in claudicant patients.

Methods: Nine Sinclair miniature pigs received a 6-mm vascular Dacron graft in the infrarenal portion of the abdominal aorta. Six pigs received grafts chemically bonded with the antimicrobials, whereas the 3rd unbonded graft served as a control. The pigs were observed for 8 weeks after graft operations. In the current phase, we attempted to determine whether the antimicrobials bonded to the graft are sufficient to prevent infection of the graft. Results: Eighty-two percent of claudicants treated with OA had moderate/severely calcified lesions. There was no significant difference in the percentage of perforations (0.6% vs 0.0%), slow flow (2.9% vs 2.0%), closure (1.4% vs 2.3%), spasm (3.8% vs 6.3%), embolism (1.7% vs 2.6%), or thrombus (1.1% vs 1.3%), in claudicants with moderate/severely calcified lesions vs without moderate/severely calcified lesions, respectively. Claudicants with moderate/severe calcium had fewer dissections than those without moderate/severely calcified lesions (10.9% vs 16.2%, p=0.004).

Conclusions: The majority of the claudicant patients in this study had lesions with moderate to severe calcification, yet the occurrence of adverse events was low after treatment with orbital atherectomy. Orbital atherectomy is a safe tool for restoring blood flow in the lower extremities of claudicant patients regardless of arterial calcium burden.